Our foundation advocates for people with Galactosemia and their families. We connect families and support networking efforts between clinicians and researchers.
Get InvolvedThe Galactosemia Foundation is urging the U.S. Food and Drug Administration (FDA) to incorporate the experiences and perspectives of people living with galactosemia in the agency’s review of govorestat (AT-007), the potential first-ever treatment for our rare genetic disease.